Sevabertinib Approved for HER2-Mutant Nonsquamous NSCLC
FDA accelerated approval makes sevabertinib available for previously treated advanced nonsquamous NSCLC with qualifying HER2 mutations, emphasizing precise molecular testing and avoiding broad HER2 eligibility.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.